2127-07-3Relevant articles and documents
On the pH-Modulated Ru-Based Prodrug Activation Mechanism
Caterino, Marco,Herrmann, Mona,Merlino, Antonello,Riccardi, Claudia,Montesarchio, Daniela,Mroginski, Maria A.,Musumeci, Domenica,Ruffo, Francesco,Paduano, Luigi,Hildebrandt, Peter,Kozuch, Jacek,Vergara, Alessandro
, p. 1216 - 1223 (2019)
The RuIII-based prodrug AziRu efficiently binds to proteins, but the mechanism of its release is still disputed. Herein, in order to test the hypothesis of a reduction-mediated Ru release from proteins, a Raman-assisted crystallographic study on AziRu binding to a model protein (hen egg white lysozyme), in two different oxidation states, RuII and RuIII, was carried out. Our results indicate Ru reduction, but the Ru release upon reduction is dependent on the reducing agent. To better understand this process, a pH-dependent, spectroelectrochemical surface-enhanced Raman scattering (SERS) study was performed also on AziRu-functionalized Au electrodes as a surrogate and simplest model system of RuII- and RuIII-based drugs. This SERS study provided a pKa of 6.0 ± 0.4 for aquated AziRu in the RuIII state, which falls in the watershed range of pH values separating most cancer environments from their physiological counterparts. These experiments also indicate a dramatic shift of the redox potential E0 by >600 mV of aquated AziRu toward more positive potentials upon acidification, suggesting a selective AziRu reduction in cancer lumen but not in healthy ones. It is expected that the nature of the ligands (e.g., pyridine vs imidazole, present in well-known RuIII complex NAMI-A) will modulate the pKa and E0, without affecting the underlying reaction mechanism.
